Image

KISQALI® has a once-daily dosing regimen:¹

• The recommended starting dose is 600 mg (3 x 200 mg tablets).
KISQALI® can be taken with or without food. Patients should be encouraged to take their dose at approximately the same time each day, preferably in the morning.

Image

†Continue treatment as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.¹
**If grade ≥2 abnormalities are observed, more frequent monitoring is recommended.¹
βCorrect electrolyte abnormalities prior to and during treatment.¹
‡Only initiate KISQALI® in patients with QTcF <450 ms. In case of QTcF prolongation during therapy, more frequent assessments are recommended.¹
AI, aromatase inhibitor; CBC, complete blood count; ECG, electrocardiogram; LFT, liver function test; LHRH, luteinising hormone-releasing hormone; QTcF, QT interval (Fridericia formula).

Image

• Dose adjustments for AEs should be made in a stepwise order by reducing the number of tablets taken.
• If dose reduction below 200 mg/day is required, treatment should be permanently discontinued.¹
• Dose modification of KISQALI® is recommended based on individual safety and tolerability as per the KISQALI (ribociclib). Prescribing Information.¹